Mach7 signs $17 million contract – share price jumps 20% at open

Shares in the ASX listed medical imaging systems provider leapt more than 20% on open.

| More on:
A businessman leaps in the air outside a city building in the CBD.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • The Mach7 share price is surging on Tuesday
  • The company announced its largest customer contract in its history
  • $7.5 million of revenue is expected to be recognised in the 2023 financial year

The Mach7 Technologies Ltd (ASX: M7T) share price is off to the races on this first day of trading in 2023.

Shares in the ASX listed medical imaging systems provider leapt more than 20% on open and are currently up 18.4% in morning trade.

Here's what's piquing ASX investor interest today.

What did the company report?

The Mach7 share price is rocketing after the company announced it has inked a multi-year deal with a Total Contract Value (TCV) of approximately $16.7 million.

The signed sales order comes from a new customer, Akumin Inc, a NASDAQ listed outpatient radiology service provider with a large footprint amongst United States' hospitals, health systems and physician groups.

The contract involves Mach7's entire Enterprise Imaging Platform including its Vendor Neutral Archive (VNA), eUnity Diagnostic Viewer and Workflow Applications. Mach7 said this will enable it to provide true cloud-based, enterprise-wide imaging and informatics solutions.

Payments for the $16.7 million 10-year capital contract will be staged annually across the life of the contract. $7.5 million of revenue is expected to be recognised in the 2023 financial year. Annual support fees are weighted to the second half of the contract term.

Commenting on the largest customer contract in the company's history, which is helping send the Mach7 share price sharply higher, CEO Mike Lampron said:

Our vendor agnostic easily integrated product suite and migration services were key requirements for the massive data ingestion and consolidation associated with Akumin's cloud-focused radiology ecosystem.

This deal together with the recent sales order received from our new partner, Nuvodia increases our exposure to the fast-growing outpatient radiology market and demonstrates that our technology appeals to customers across the size spectrum.

Mach7 share price snapshot

The Mach7 share price went backwards in 2022, as you can see in the chart below. But longer-term investors are unlikely to be complaining, with shares up 211% over the past five years. For some context, the All Ordinaries Index (ASX: XAO) has gained 15% over that same period.

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Mach7 Technologies. The Motley Fool Australia has recommended Mach7 Technologies. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Should I buy the dip on CSL shares?

A leading fund manager gives his verdict on the growth prospects for CSL shares.

Read more »

A woman relaxes on a yellow couch with a book and cuppa, and looks pensively away as she contemplates the joy of earning passive income.
Healthcare Shares

NIB shares have soared 24% this year. Does Macquarie expect this to continue?

Will this private health insurer continue to deliver big returns? Let's find out.

Read more »

Woman presenting financial report on large screen in conference room.
Healthcare Shares

Up nearly 30% in a year, should I buy Fisher & Paykel shares before its earnings result?

Will the ASX 200 healthcare stock continue to outperform?

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

CSL shares among most expensive on ASX. Is now a good time to buy?

Analysts predict CSL share price growth will keep on coming.

Read more »

A man looking at his laptop and thinking.
Healthcare Shares

Should you buy the dip in the ResMed share price?

Let's see what one leading broker is saying following yesterday's pullback.

Read more »

A woman puts up her hands and looks confused while sitting at her computer.
Healthcare Shares

Down 5%: What's going on with the ResMed share price?

Let's see what has spooked investors today and caused them to push the sell button.

Read more »

Beautiful young woman drinking fresh orange juice in kitchen.
Healthcare Shares

Guess which ASX 300 stock is jumping 11% on big news

This stock is having a day to remember on Thursday. But why?

Read more »

A group of medical researchers stands side by side with each other wearing white coats in their research laboratory with scientific equipment in the background.
Healthcare Shares

Trump executive order to hit these 3 ASX pharmaceutical stocks

Donald Trump’s new executive order caused these 3 ASX pharmaceutical stocks to crash on Monday.

Read more »